SCHEMBL863047

SCHEMBL863047

NOCCl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3935036 0.67
Hydrochloric Acid SCHEMBL933918 0.65
Methoxyamine SCHEMBL5626709 0.63
SCHEMBL11012286 0.59
SCHEMBL12239869 0.59
SCHEMBL252965 0.59
SCHEMBL6436737 0.59
SCHEMBL998 0.59
SCHEMBL7648923 0.58
SCHEMBL5308881 0.56

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170105963-A1 SMALL MOLECULES THAT INDUCE INTRINSIC PATHWAYS APOPTOSIS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2017-04-20 US disclosed
WO-2016061370-A1 PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION NOVARTIS AG (CH) 2016-04-21 WO disclosed
WO-2015109014-A1 NO-RELEASING NONOATE(OXYGEN-BOUND)CHROMENE CONJUGATES Euclises Pharmaceuticals, Inc. (US) 2015-07-23 WO disclosed
WO-2015109017-A2 DEUTERATED NO-RELEASING NONOATE(OXYGEN-BOUND)CHROMENE CONJUGATES Euclises Pharmaceuticals, Inc. (US) 2015-07-23 WO disclosed
US-8178539-B2 Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-05-15 US disclosed
US-8143270-B2 2-amino 1H-in-imidazo ring systems and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-03-27 US disclosed
US-8034938-B2 Imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a CH( R1) group in the fused ring at 1-position of imidazo ring; modulate immune response, by induction of cytokine biosynthesis or other mechanism 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-10-11 US disclosed
US-7906506-B2 Immunomodulators, inducing cytokine biosynthesis in animals; antiviral agents, antitumor agents; e.g. (11S)-1-Methyl-8-propyl-10,11-dihydro-8H-[1,4]oxazino[4',3':1,2]imidazo[4,5-c]quinolin-6-amine 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-03-15 US disclosed
US-20100173906-A1 Substituted 3,4,6,7-Tetrahydro-5H-1,2a,4a,8-Tetraazacyclopenta[cd]Phenalenes and Methods 3M INNOVATIVE PROPERTIES COMPANY 2010-07-08 US disclosed
US-7648997-B2 Immunomodulators for inducing cytokine biosynthesis, for treatment of diseases including viral and neoplastic diseases; 1-[3-(Aminooxy)propyl]-2-propyl-1H-imidazo[4,5-c]quinolin-4-amine; N-[3-(4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)propoxy]cyclopropanecarboxamide COLEY PHARMACEUTICAL GROUP, INC. (US) 2010-01-19 US disclosed
US-20090298821-A1 HYDROXY AND ALKOXY SUBSTITUTED IH-IMIDAZONAPHTHYRIDINES AND METHODS PFIZER INC. 2009-12-03 US disclosed
US-20090105295-A1 HYDROXYLAMINE SUBSTITUTED IMIDAZOQUINOLINES COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-04-23 US disclosed
US-20090023720-A1 2-Amino 1H-Imidazo Ring Systems and Methods 3M INNOVATIVE PROPERTIES COMPANY 2009-01-22 US disclosed
US-20080114019-A1 Hydroxylamine Substituted Imidazoquinolines COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-05-15 US disclosed
US-20080085895-A1 Substituted Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds 3M INNOVATIVE PROPERTIES COMPANY 2008-04-10 US disclosed
US-20080070907-A1 Substituted chiral fused [1,2] imidazo [4,5-C] ring compounds and methods COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-03-20 US disclosed